Discovery and development of novel antibiotics to treat multidrug-resistant infections.
Specialized in fusion molecules based on secondary metabolites from eukaryotes.
Developing game-changing alternatives to fossil-based plastics
Developing first-in-class therapeutics for novel intervention of disabling skin conditions
Arxx Therapeutics develops a first-in-class monoclonal antibody with a unique mechanism of action targeting non-resolving tissue fibrosis
Developing diagnostic self-tests
Bringing safe and affordable drinking water to low income communities.